1065 related articles for article (PubMed ID: 34706720)
1. Development and validation of a novel lipid metabolism-related gene prognostic signature and candidate drugs for patients with bladder cancer.
Zhu K; Xiaoqiang L; Deng W; Wang G; Fu B
Lipids Health Dis; 2021 Oct; 20(1):146. PubMed ID: 34706720
[TBL] [Abstract][Full Text] [Related]
2. Identification of a novel signature based on unfolded protein response-related gene for predicting prognosis in bladder cancer.
Zhu K; Xiaoqiang L; Deng W; Wang G; Fu B
Hum Genomics; 2021 Dec; 15(1):73. PubMed ID: 34930465
[TBL] [Abstract][Full Text] [Related]
3. Identification of a novel defined inflammation-related long noncoding RNA signature contributes to predicting prognosis and distinction between the cold and hot tumors in bladder cancer.
Xiong X; Chen C; Li X; Yang J; Zhang W; Wang X; Zhang H; Peng M; Li L; Luo P
Front Oncol; 2023; 13():972558. PubMed ID: 37064115
[TBL] [Abstract][Full Text] [Related]
4. TFRC, associated with hypoxia and immune, is a prognostic factor and potential therapeutic target for bladder cancer.
Tang R; Wang H; Liu J; Song L; Hou H; Liu M; Wang J; Wang J
Eur J Med Res; 2024 Feb; 29(1):112. PubMed ID: 38336764
[TBL] [Abstract][Full Text] [Related]
5. Identifying a Novel Defined Pyroptosis-Associated Long Noncoding RNA Signature Contributes to Predicting Prognosis and Tumor Microenvironment of Bladder Cancer.
Lu H; Wu J; Liang L; Wang X; Cai H
Front Immunol; 2022; 13():803355. PubMed ID: 35154117
[TBL] [Abstract][Full Text] [Related]
6. Construction of a novel mRNA-signature prediction model for prognosis of bladder cancer based on a statistical analysis.
Li J; Cao J; Li P; Yao Z; Deng R; Ying L; Tian J
BMC Cancer; 2021 Jul; 21(1):858. PubMed ID: 34315402
[TBL] [Abstract][Full Text] [Related]
7. Identification of a chromatin regulator signature and potential candidate drugs for bladder cancer.
Zhu K; Liu X; Deng W; Wang G; Fu B
Hereditas; 2022 Feb; 159(1):13. PubMed ID: 35125116
[TBL] [Abstract][Full Text] [Related]
8. Prognosis analysis and validation of lipid metabolism-associated lncRNAs and tumor immune microenvironment in bladder cancer.
Tan Z; Fu S; Zuo J; Wang J; Wang H
Aging (Albany NY); 2023 Aug; 15(16):8384-8407. PubMed ID: 37632832
[TBL] [Abstract][Full Text] [Related]
9. An effective N6-methyladenosine-related long non-coding RNA prognostic signature for predicting the prognosis of patients with bladder cancer.
Ma T; Wang X; Meng L; Liu X; Wang J; Zhang W; Tian Z; Zhang Y
BMC Cancer; 2021 Nov; 21(1):1256. PubMed ID: 34802433
[TBL] [Abstract][Full Text] [Related]
10. Identification of a Novel PPAR Signature for Predicting Prognosis, Immune Microenvironment, and Chemotherapy Response in Bladder Cancer.
Zhu K; Deng W; Deng H; Liu X; Wang G; Fu B
PPAR Res; 2021; 2021():7056506. PubMed ID: 35027921
[TBL] [Abstract][Full Text] [Related]
11. Identification of a tumor microenvironment-related seven-gene signature for predicting prognosis in bladder cancer.
Wang Z; Tu L; Chen M; Tong S
BMC Cancer; 2021 Jun; 21(1):692. PubMed ID: 34112144
[TBL] [Abstract][Full Text] [Related]
12. A novel focal adhesion-related risk model predicts prognosis of bladder cancer -- a bioinformatic study based on TCGA and GEO database.
Hu J; Wang L; Li L; Wang Y; Bi J
BMC Cancer; 2022 Nov; 22(1):1158. PubMed ID: 36357874
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic Benefits and Prognostic Value of a Model Based on 7 Immune-associated Genes in Bladder Cancer.
Cao M; Cao Y; Xue S; Zhang Q; Zhang H; Xue W
Altern Ther Health Med; 2024 Apr; 30(4):130-138. PubMed ID: 38518167
[TBL] [Abstract][Full Text] [Related]
14. Multi-Omics analysis identifies a lncRNA-related prognostic signature to predict bladder cancer recurrence.
Xu Z; Chen H; Sun J; Mao W; Chen S; Chen M
Bioengineered; 2021 Dec; 12(2):11108-11125. PubMed ID: 34738881
[TBL] [Abstract][Full Text] [Related]
15. A TP53-Associated Immune Prognostic Signature for the Prediction of Overall Survival and Therapeutic Responses in Muscle-Invasive Bladder Cancer.
Wu X; Lv D; Cai C; Zhao Z; Wang M; Chen W; Liu Y
Front Immunol; 2020; 11():590618. PubMed ID: 33391264
[TBL] [Abstract][Full Text] [Related]
16. Identification of a Prognosis-Related Risk Signature for Bladder Cancer to Predict Survival and Immune Landscapes.
Wang L; Wang Y; Wang J; Li L; Bi J
J Immunol Res; 2021; 2021():3236384. PubMed ID: 34708131
[TBL] [Abstract][Full Text] [Related]
17. Tumor Expression Profile Analysis Developed and Validated a Prognostic Model Based on Immune-Related Genes in Bladder Cancer.
Dong B; Liang J; Li D; Song W; Zhao S; Ma Y; Song J; Zhu M; Yang T
Front Genet; 2021; 12():696912. PubMed ID: 34512722
[No Abstract] [Full Text] [Related]
18. Identification and Validation of an Individualized Prognostic Signature of Bladder Cancer Based on Seven Immune Related Genes.
Qiu H; Hu X; He C; Yu B; Li Y; Li J
Front Genet; 2020; 11():12. PubMed ID: 32117435
[TBL] [Abstract][Full Text] [Related]
19. Identification and validation of telomerase related lncRNAs signature to predict prognosis and tumor immunotherapy response in bladder cancer.
Chen X; Qin Z; Zhu X; Wang L; Li C; Wang H
Sci Rep; 2023 Dec; 13(1):21816. PubMed ID: 38071230
[TBL] [Abstract][Full Text] [Related]
20. A TP53-based immune prognostic model for muscle-invasive bladder cancer.
Li H; Lu H; Cui W; Huang Y; Jin X
Aging (Albany NY); 2020 Dec; 13(2):1929-1946. PubMed ID: 33323544
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
